Praxis Precision Medicines Inc Ordinary Shares PRAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines Says FDA Extends Review of Relutrigine Application
Trading Information
- Previous Close Price
- $346.21
- Day Range
- $319.24–343.71
- 52-Week Range
- $160.11–392.70
- Bid/Ask
- $318.00 / $327.00
- Shares Outstanding
- 27.95M
- Market Cap
- $9.08B
- Volume/Avg
- 590,079 / 457,755
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 10,998
Valuation
Metric | PRAX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.21 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | PRAX |
|---|---|
Quick Ratio | 14.20 |
Current Ratio | 14.53 |
Interest Coverage | — |
Quick Ratio
PRAX
Profitability
Metric | PRAX |
|---|---|
Return on Assets (Normalized) | −27.85% |
Return on Equity (Normalized) | −29.26% |
Return on Invested Capital (Normalized) | −29.24% |
Return on Assets
PRAX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|VW#Vg^g | LOCK|%QKs | $138B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Kl@<zkl | LOCK|Bvmcx | $98B | |||
| Moderna Inc MRNA | LOCK|b>>Vc> | LOCK|d$ | $94B | |||
| argenx SE ADR ARGX | LOCK|!f#R>Zg | LOCK|Zj% | $62B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|?%nvTC! | LOCK|F#& | $50B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&NBfz#? | LOCK|vX^f | $31B | |||
| Incyte Corp INCY | LOCK|Dj>QCqv | LOCK|b^d | $25B | |||
| BioNTech SE ADR BNTX | LOCK|<@sgpDN | LOCK|<x$ | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|mHPVQMD | LOCK|kzPG | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|KWrkmt | LOCK|^ql | $15B |
United States